I am surprised that a big Pharma hasn't stepped up yet. For a few million, Bayer could protect their Aleve franchise. The cost of the phase III trials will cost a few million up front and Antibe would require some cash to survive until drug approval but for someone like Bayer, it's not much.
Plus if the drug is successful, their cost to payoff Antibe is in future royalty payments and is only payable IF ATB-346 is approved and sold to the public.
If they don't JV or buy Antibe, they risk losing 300 million a year in sales. Whoever funds Antibe is going to market the advantages hard and Aleve won't look good in the comparisons.
Maybe there is a risk to approval that I'm not seeing or maybe there are better pain relievers on the horizon that Bayer would rather invest in.
I will hold Antibe at least until next year when the dosage trial is over. I am expecting positive results and eventually a JV.
News 
Market Data 
Discover 
